Zobrazeno 1 - 10
of 10
pro vyhledávání: '"Mengjie Niu"'
Autor:
Jingwen Xia, Li Yang, Liang Dong, Mengjie Niu, Shengli Zhang, Zhiwei Yang, Gulinuer Wumaier, Ying Li, Xiaomin Wei, Yi Gong, Ning Zhu, Shengqing Li
Publikováno v:
Frontiers in Pharmacology, Vol 9 (2018)
Prostacyclin receptor (IP) and peroxisome proliferator-activated receptor-gamma (PPARγ) are both potential targets for treatment of pulmonary arterial hypertension (PAH). Expression of IP and PPARγ decreases in PAH, suggesting that screening of dua
Externí odkaz:
https://doaj.org/article/2ced9420f362440c88d50540bdf62553
Autor:
Jian He, Ying Li, Shengqing Li, Tianxing Hang, Liying Fang, Liang Dong, Xiujuan Zhang, Jingwen Xia, Mengjie Niu, Yaqin Chai
Publikováno v:
Oncology Letters
First-generation epithelial growth factor receptor tyrosine kinase inhibitors (EGFR-TKIs) have markedly improved the treatment of non-small cell lung cancer (non-SCLC) with EGFR-sensitive mutations. However, acquired resistance to these drugs was ine
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::a518adc0187995c1acbb2f4712f0f709
https://doi.org/10.3892/ol.2017.6229
https://doi.org/10.3892/ol.2017.6229
Autor:
Yi Gong, Liang Dong, Yuanyuan Zhang, Ying Li, Shengli Zhang, Mengjie Niu, Li Yang, Ning Zhu, Zhiwei Yang, Shengqing Li, Xiaomin Wei, Peng Zhang, Youzhi Zhang, Jing Zhang, Xiujuan Zhang, Jingwen Xia
Publikováno v:
Acta Pharmacol Sin
Abnormal wound healing by pulmonary artery smooth muscle cells (PASMCs) promotes vascular remodeling in hypoxia-induced pulmonary hypertension (HPH). Increasing evidence shows that both the mammalian target of rapamycin complex 1 (mTORC1) and nuclear
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::5a79664bbe22cec572617939a30c8a78
https://pubmed.ncbi.nlm.nih.gov/31316183
https://pubmed.ncbi.nlm.nih.gov/31316183
Publikováno v:
The Clinical Respiratory Journal. 11:906-914
Backgrounds Pulmonary sarcoidosis is often complicated by pulmonary hypertension, a complication that is associated with increased disability and mortality. To this point, however, little progress has been made in the treatment of sarcoidosis associa
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::8a4b2e741d70e02c4ece1f0958616a68
https://doi.org/10.1111/crj.12435
https://doi.org/10.1111/crj.12435
Autor:
Li Yang, Lingli Liu, Xinpeng Han, Yongping Yu, Shuoyao Qu, Yuhai Zhang, Yaqin Chai, Xuemin Yang, Jingwen Xia, Liang Dong, Mengjie Niu, Ning Zhu, Shengqing Li, Liying Fang
Publikováno v:
The clinical respiratory journal. 12(11)
Background The incidence and risk factors of chronic thromboembolic pulmonary hypertension (CTEPH) in patients with acute pulmonary embolism (PE) have been well reported. However, in real world, patients diagnosed with PE for the first time were usua
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::63dfb327bc5f4f069ae18e14ef0f33b1
https://pubmed.ncbi.nlm.nih.gov/30160381
https://pubmed.ncbi.nlm.nih.gov/30160381
Autor:
Mengjie Niu, Zhiwei Yang, Ying Li, Liang Dong, Li Yang, Jingwen Xia, Xiaomin Wei, Yi Gong, Gulinuer Wumaier, Shengli Zhang, Ning Zhu, Shengqing Li
Publikováno v:
Frontiers in Pharmacology
Frontiers in Pharmacology, Vol 9 (2018)
Frontiers in Pharmacology, Vol 9 (2018)
Prostacyclin receptor (IP) and peroxisome proliferator-activated receptor-gamma (PPARγ) are both potential targets for treatment of pulmonary arterial hypertension (PAH). Expression of IP and PPARγ decreases in PAH, suggesting that screening of dua
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::a0eb92453a0217a1d9390c3de15f0d2c
http://europepmc.org/articles/PMC5829529
http://europepmc.org/articles/PMC5829529
Autor:
Yongping Yu, Yaqin Chai, Xinpeng Han, Yuhai Zhang, Shengqing Li, Liying Fang, Shuoyao Qu, Liang Dong, Mengjie Niu, Xuemin Yang, Lingli Liu
Publikováno v:
Respiratory care. 62(4)
BACKGROUND: Monotherapy and sequential combination therapy have been widely used in the treatment of pulmonary arterial hypertension (PAH). There is limited evidence for initial combination therapy in patients with PAH, particularly those with World
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::05edcf64f5a7ae669ca2f7b1928785a4
https://pubmed.ncbi.nlm.nih.gov/28119496
https://pubmed.ncbi.nlm.nih.gov/28119496
Publikováno v:
The clinical respiratory journal. 11(6)
Pulmonary sarcoidosis is often complicated by pulmonary hypertension, a complication that is associated with increased disability and mortality. To this point, however, little progress has been made in the treatment of sarcoidosis associated with pul
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid________::1961fbf0698485dffb8d804d4359f99d
https://pubmed.ncbi.nlm.nih.gov/26666961
https://pubmed.ncbi.nlm.nih.gov/26666961
Autor:
LIYING FANG, JINGWEN XIA, LIANG DONG, XIUJUAN ZHANG, MENGJIE NIU, TIANXING HANG, SHENGQING LI, YAQIN CHAI, YING LI
Publikováno v:
Oncology Letters; Jul2017, Vol. 14 Issue 1, p593-598, 6p, 1 Color Photograph, 1 Chart
Autor:
Xinpeng Han, Yuhai Zhang, Liang Dong, Liying Fang, Yaqin Chai, Mengjie Niu, Yongping Yu, Lingli Liu, Xuemin Yang, Shuoyao Qu, Shengqing Li
Publikováno v:
Respiratory Care; Apr2017, Vol. 62 Issue 4, p489-496, 8p, 1 Diagram, 5 Charts, 1 Graph